Big data identifies lipids as signatures of health and disease

Biology is swaddled in lipids: fats, oils, and even waxes envelop cells and their organelles, mediate the flow of vast biological information networks, protect fragile tissues, and store essential energy across multiple organisms. But despite their importance, lipids have traditionally been among the hardest biomolecules to study because of the diversity of their molecular structures, which are not determined by the well-defined building blocks and simple rules that govern DNA, RNA, and proteins. And this diversity means that, unlike building and analyzing genome and transcriptome databases, lipids require more customized analytic procedures.

Because of this, it is very difficult to study either the physiological function of a vast majority of lipid species or the way they are so precisely regulated in cells. But while lipidomics technologies are progressing, translating their findings into medical applications and introducing them into clinical laboratories is still a considerable challenge.

This is the challenge that the team of Johan Auwerx at EPFL, in collaboration with Dave Pagliarini's group at the University of Wisconsin-Madison took on by measuring almost 150 lipid species in the blood and liver of mice. They also followed this up by identifying the genetic regulators of each lipid species as well as their physiological functions.

The researchers used systems genetics approaches to combine the lipidomics data with other "omics" datasets (phenomics, proteomics, transcriptomics) from this population of mice (so-called BXD). The approach identified plasma and blood lipid species from different lipid classes as signatures of healthy or unhealthy metabolic states.

For example, the scientists demonstrated seven plasma triglyceride species as signatures of healthy or fatty liver and non-alcoholic fatty liver disease (NAFLD). Their observation was validated in an independent dietary and therapeutic model of NAFLD in mice and in plasma from patients with NAFLD.

"This finding fuels optimism that lipid species could serve as signatures or biomarkers that will replace the invasive tissue biopsies currently used to diagnose diseases such as NAFLD - simply by measuring specific lipid species in the blood," says Johan Auwerx.

In a companion paper published at the same time, the authors identify as signatures of healthy or fatty liver a subset of the cardiolipin lipids, which are the essential phospholipids in the inner membrane of mitochondria.

In both papers, the researchers pinpoint several genetic locations that may regulate the production of lipid species. By comparing the genetic data from the BXD mouse population to data from so-called genome-wide association studies of lipid-related disorders in humans, they were able to identify common genes between mice and humans that regulate lipids.

"Analyzing lipids and finding their physiological role may never be as straightforward as studying nucleic acids or proteins," says Auwerx. "But these companion studies provide a foundation for understanding the genetic regulation and physiological significance of lipid species, while yet again demonstrating the potential of Big Data mining to address biological and clinical questions."

Pooja Jha, Molly T McDevitt, Emina Halilbasic, Evan G Williams, Pedro M Quiros, Karim Gariani, Maroun B Sleiman, Rahul Gupta, Arne Ulbrich, Adam Jochem, Joshua J Coon, Michael Trauner, David J Pagliarini, Johan Auwerx.
Genetic regulation of plasma lipid species and their association with metabolic phenotypes.
Cell Systems 13 June 2018. doi: 10.1016/j.cels.2018.05.009.

Pooja Jha, Molly T McDevitt, Rahul Gupta, Pedro M Quiros, Evan G Williams, Karim Gariani, Maroun B Sleiman, Leo Diserens, Adam Jochem, Arne Ulbrich, Joshua J Coon, Johan Auwerx, David J Pagliarini.
Systems analyses reveal physiological roles and genetic regulators of liver lipid species.
Cell Systems 13 June 2018. doi: 10.1016/j.cels.2018.05.016.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Mushrooms of the Far East hold promise for the ant…

Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities ...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...

Atacand to be divested to Cheplapharm in Europe

AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorot...